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Abstract Although many lines of evidence have suggested that 
angiotensin II (Ang II) plays an important role in development 
of cardiac hypertrophy, the mechanism by which Ang II increases 
protein synthesis in cardiac myocytes remains unclear. It has been 
reported that the phosphorylation of $6 protein in 40 S ribosome 
is correlated to the efficiency of protein synthesis. In the present 
study, we have examined whether Ang II activates p70 $6 kinase 
(p70S6g), which has been reported to phosphorylate $6 protein. 
Ang II activated p70 s6K through ATI receptor. An immunosup- 
pressant agent, rapamycin, inhibited Ang II-induced p70 s6K acti- 
vation but not the activation of MAP kinases or the induction of 
c-fos gene expression. Rapamycin also abolished Ang II-induced 
increase in protein synthesis. These results suggest hat Ang II 
induces cardiac hypertrophy by activating p70 s6K. 
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1. Introduction 
Many lines of evidence have suggested that angiotensin II 
(Ang II) plays a critical role in inducing cardiac hypertrophy 
[1-7]. All components of the renin angiotensin system such as 
renin, angiotensinogen a d angiotensin-converting e zyme 
(ACE) have been identified in the heart at both mRNA and 
protein levels [5,6]. It has been reported that angiotensinogen 
and ACE mRNAs are increased in experimental left ventricular 
hypertrophy induced by hemodynamic overload [4]. ACE in- 
hibitors with subpressor doses induced significant regression of 
cardiac hypertrophy with no change in systemic systolic blood 
pressure [1]. Our and other laboratories have reported that Ang 
II activates phosphorylation cascades of protein kinases uch 
as protein kinase C (PKC), mitogen-activated protein (MAP) 
kinases and 90 kDa $6 kinase (p90rsk), and induces the expres- 
sion of both immediate arly response genes and fetal type 
genes, followed by the increase in protein synthesis in cultured 
cardiac myocytes [7-9]. 
In general, cardiac hypertrophy is formed by the increase in 
protein synthesis and/or the decrease in protein degradation. 
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The efficiency of protein synthesis is well-correlated to 
phosphorylated levels of $6 protein in 40 S ribosome [10-12]. 
Two distinct families of $6 kinases that phosphorylate $6 pro- 
tein in vitro have been identified [10]. One of them is the 90 kDa 
$6 kinase (p90 rsk) and the other is the 70 kDa $6 kinase (p70S6K). 
The p90 rsk is activated by MAP kinases through Ras-Raf path- 
way and mainly mediates the control of transcription. Although 
the signaling pathway that leads to activation of p70 s6K is still 
unclear, many reports have suggested that p70 s6K is responsible 
for phosphorylation f $6 protein in vivo and mediates the 
control of translation [10-12]. In the present study, to elucidate 
the mechanism of cardiac hypertrophy, we examined the role 
of p70 s6K in cardiac hypertrophy induced by Ang II. 
2. Materials and methods 
2.1. Culture of cardiomyocytes 
Primary cultures of cardiomyocytes were prepared from ventricles of
1-day-old Wistar rats, as described previously [8], basically according 
to the method of Simpson and Savion [13]. Cardiomyocytes were plated 
at a field density of 1 × 103 cells/mm z on 35-mm or 100-mm culture 
dishes. After starvation for 48 h, cardiomyocytes were stimulated by 
Ang II (Sigma). 
2.2. Kinase assay of p70 sr~ 
Cardiac myocytes cultured in 35-mm culture dishes were stimulated 
with Ang II for the indicated periods of time at 37°C. After stimulation, 
the cells were washed twice with ice-cold PBS and lysed with 0.15 ml 
of Triton X-100 lysis buffer (50 mM Tris-HC1, pH 7.4, 100 mM NaCI, 
50 mM NaF, 5 mM EDTA, 40 mM fl-glycerophosphate, 1 mM sodium 
orthovanadate, 10-4 M phenylmethylsulfonyl fluoride, 10 -6 M leu- 
peptin, 10 -6 M pepstatin A, 1% Triton X-100) for 25 min on ice. Cell 
lysates (100 ~tg) were incubated for 12 h at 4°C with anti-p70 s6K poly- 
clonal antibody (Santa Cruz Biotechnology) preabsorbed to protein 
A-Sepharose b ads. The immune complexes were washed 3× with lysis 
buffer and once with kinase buffer (20 mM N-2-hydroxyethyl- 
piperazine-N'-2-ethanesulfonic acid (HEPES), pH 7.4, 10 mM MgC12, 
1 mM dithiothreitol (DTT), 10 mM fl-glycerophosphate). The im- 
munoprecipitates w re resuspended in 40/tl of kinase buffer containing 
0.2 mM $6 peptide (RRRLSSLRA, Santa Cruz Biotechnology), 20/IM 
ATE and 5 pCi of [y-32p]ATP (3000 Ci/mmol) and incubated at 30°C 
for 20 min. After incubation, the reactions were stopped by spotting the 
mixture on P81 paper (Whatman). The filters were washed 3× for l0 
min each in 1% phosphoric acid, once in acetone and dried. The 32p 
uptake was measured by Cerenkov counting method. 
2.3. MAP kinase assays in myelin basic protein (MBP)-containing gels 
MAP kinase assays were performed using MBP-containing gels as 
described previously [9]. 
2.4. Northern blot analysis 
After starvation for 48 h, cardiac myocytes in 100-mm dishes were 
stimulated with Ang II (10 -6 M) for 30 min at 37°C. Northern blot 
analysis was performed using 32P-labeled human c-fos cDNA as de- 
scribed previously [14]. 
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2.5. Amino acid uptake into cardiomyocytes 
After starvation for 48 h, cardiac myocytes were stimulated with 10 -6 
M Ang II for 24 h. The relative amount of protein synthesis was 
determined by assessing the incorporation of the radioactivity into a 
trichloroacetic a id-insoluble fraction as previously reported [8,9]. 
3. Results 
3.1. Ang H stimulates p70 s6K in cardiac myocytes 
To examine whether Ang II stimulates pT0 s6K in cultured 
cardiac myocytes of neonatal rats, we measured the activity of 
p70 s6K using a specific antibody raised against a carboxyl-ter- 
minal peptide from the rat p70 s6K. This antibody specifically 
recognizes p70 s6K but not p90 rsk in mouse, rat and human cells. 
At 48 h after serum deprivation, cardiac myocytes were stimu- 
lated with Ang II (10 -6 M). The p70 s6K activity started to in- 
crease by 5 min after the stimulation, and peaked at 15 min 
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Fig. 1. Time course and dose dependence of Ang II-induced p70 srK 
activation. (A, above) Cardiac myocytes of neonatal rats were stimu- 
lated with 10 -6 M Ang II for various periods of time. (B, below) Cardiac 
myocytes were stimulated with various concentrations of Ang II for 15 
rain. The activity of p70 s6K was measured asdescribed insection 2. Data 
represent the average percentage of control (= 100%, vehicle) from four 
independent experiments (mean + S.E.M.). Statistical nalysis was per- 
formed using the paired-sample t-test with P values corrected by the 
Bonferroni method (*P < 0.05 and *P < 0.01 vs. control). 
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Fig. 2. Ang II activates pT0 s6K through AT1 receptor. Cardiac myocytes 
were pretreated with 10 -5 M losartan or 10 -5 M PD123319 for 30 min 
and stimulated with 10 -6 M Ang II for 15 min. p70 srK activity was 
measured as described. Data represent the average percentage of con- 
trol (= 100%, vehicle) from three independent experiments 
(mean _+ S.E.M.) (*P < 0.05 vs. control). 
(Fig. 1A). The activity decreased gradually thereafter and re- 
turned to the control level at 4 h after stimulation (data not 
shown). Cardiac myocytes were next stimulated with various 
concentrations (10 -9 to 10 -5 M) of Ang II for 15 min (Fig. 1B). 
A slight increase in p70 s6K activity was observed at 10 -9 M, and 
the maximal activation of p70 sr~ was obtained at 10 -6 M of Ang 
II. The activity of p70 s6K was increased by 110% with 10 -6 M 
of Ang II as compared with that of control. 
3.2. Ang H stimulates p70 s6K through AT1 receptor 
Two kinds of Ang II receptors, AT1 and AT2, have been 
reported to exist in cardiac myocytes [15-19]. To examine 
which subtype of Ang II receptors i involved in the activation 
of p70 s6K, cardiac myocytes were preincubated with AT 1 recep- 
tor-specific antagonist, losartan (10 -5 M) or AT2 receptor-spe- 
cific antagonist, PD123319 (10 -5 M) for 30 min and then stim- 
ulated with Ang II (10 -6 M) for 15 min. Losartan completely 
inhibited the Ang II-induced p70 s6K activation, whereas 
PD123319 had no effect (Fig. 2). These results suggest hat 
p70 s6K is activated by Ang II through AT1 receptor. 
3.3. Rapamycin but not FK506 inhibits p70 S6K activation by 
Ang H 
Although the immunosuppressant gents rapamycin and 
FK506 are structurally related macrolides, it has been reported 
that subnanomolar concentrations of rapamycin but not 
FK506 specifically block serum-induced p70 s6K activation in 
Swiss 3T3 cells [2024]. To examine whether rapamycin i hibits 
the activation of p70 s6K by Ang II, cardiac myocytes were 
pretreated with rapamycin (0.01-10 ng/ml) or FK506 (30 ng/ml) 
for 30 min prior to stimulation with Ang II (10 -6 M) .  The 
activity of p70 s6K enhanced by Ang II decreased to the control 
levels by the treatment with 0.1 ng/ml rapamycin. One ng/ml 
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Fig. 3. Rapamycin inhibits p70 s6K activated by Ang II. Cardiac my- 
ocytes were pretreated with various concentrations of rapamycin or 30 
ng/ml of FK506 for 30 min and stimulated with 10 -6 M Ang II for 15 
min. p70 s6K activity was measured as described. Data represent the 
average percentage ofcontrol (= 100%, vehicle) from three independent 
experiments (mean + S.E.M.) (*P < 0.05 and *P < 0.01 vs. control). 
rapamycin reduced the p70 s6K activity to 25% of unstimulated 
basal evels whereas even high concentration of FK506 had no 
effect on the p70 s6K activity (Fig. 3). 
3.4. p70 s6K activath~n & necessary for Ang II-induced cardiac 
hypertrophy 
To examine the role of p70 s6K in Ang lI-induced cardiac 
hypertrophy, we measured the relative protein synthesis using 
[3H]phenylalanine i  the absence or presence of rapamycin. As 
described in the previous papers [9], we found that Ang II (10 -6 
M) increased phenylalanine incorporation into cardiac my- 
ocytes by approximately 1.4-fold as compared with control 
(Fig. 4). Rapamycin (0.5 ng/ml) completely blocked the Ang 
II-induced increase in amino acid incorporation, suggesting 
that p70 s6K may play a critical role in Ang II-induced cardiac 
hypertrophy. 
3.5. p70 s6r activation is independent of MAP kinase activation 
and c-fos gene expression 
Our and other laboratories have recently reported that Ang 
II increases the activity of Raf-1 and MAP kinases, and mRNA 
levels of c-fos through the AT1 receptor in cardiac myocytes 
[7,8]. To elucidate the relation between signaling pathways that 
induce the activation of p70 s6~ and MAP kinases, we measured 
the activity of MAP kinases after Ang II stimulation in the 
presence or absence of rapamycin. Ang II activated MAP ki- 
nases as previously reported (Fig. 5A, lane 2) [8,9]. Rapamycin 
as well as FK506 did not inhibit Ang II-induced the activation 
of MAP kinases (Fig. 5A, lane 3 and 4). We next examined 
whether p70 s6K is involved in the Ang II-induced c-fos gene 
expression i  cardiac myocytes. Ang II induced c-fos gene ex- 
pression as reported before [7-9] and rapamycin or FK506 did 
not inhibit the Ang II-induced c-fos gene expression (Fig. 5B). 
These data suggest hat the pathway of p70 s6R activation is 
different from that of MAP kinase activation and of c-los gene 
expression in cardiac myocytes. 
4. Discussion 
A growing body of data has suggested that renin-angiotensin 
system plays an important role in generating cardiac hypertro- 
phy [1-7]. In the present study, to elucidate the mechanism of 
the Ang II-induced cardiac hypertrophy, we examined the role 
of p70 s6K in cultured cardiac myocytes of neonatal rats. Ang 
II increased the activity of p70 s6K, and rapamycin but not 
FK506 completely inhibited the activation. Rapamycin also 
inhibited the Ang II-induced increase in protein synthesis, but 
had no effects on the Ang II-induced MAP kinase activation 
and c-los gene expression. 
It has been reported that $6 protein exists at the tRNA- 
mRNA-binding site of 40 S ribosome and that phosphorylation 
of five serine residues at the carboxyl-terminus of $6 protein is 
well-correlated to the efficiency of protein synthesis [l 1,12]. 
Although the signaling pathway that leads to activation of 
p70 s6K is still unclear, many reports have suggested that p70 s6R 
is responsible for phosphorylation of $6 protein in vivo and 
regulates the efficiency of translation. In the present study, Ang 
II activated p70 s6K from as early as 5 min in cardiac myocytes. 
The peak of p70 s6K activation was observed at 15 min and the 
increased activity above basal evels continued for 4 h after Ang 
II addition (Fig. 1). The maximum activation was obtained by 
10 -6 M Ang II and half maximum activation by ~5 × 10 -9 M 
Ang II. Since losartan completely blocked the Ang II-induced 
activation of p70 s6K, Ang II activates p70 s6K through AT1 re- 
ceptor. The Ang II concentrations and the receptor type which 
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Fig. 4. Rapamycin inhibits Ang II-induced phenylalanine incorpora- 
tion. After pretreatment wi h rapamycin (0.5 ng/ml), cardiac myocytes 
were stimulated by 10 -6 M Ang II for 24 h and [3H]phenylalanine 
(1 /zCi/ml) was added 2 h before harvest. The total radioactivity of
incorporated [3H]phenylalanine was determined by liquid scintillation 
counting. Data represent the average percentage of control (= 100%, 
vehicle) from three independent experiments (mean +_ S.E.M.) 
(~P < 0.01 vs. control). 
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Fig. 5. Rapamycin does not inhibit Ang II-induced MAP kinase activa- 
tion and c-fos gene expression. (A, above) MAP kinase assays using 
MBP-containing els. Cardiac myocytes were pretreated for 30 minutes 
with rapamycin (0.5 ng/ml) or FK506 (10 ng/ml) and stimulated with 
10 -6 M Ang II for 8 min. lane 1, control; lane 2, Ang II; lane 3, Ang 
II+rapamycin; lane 4, Ang II + FK506. MAP kinase activity was meas- 
ured using MBP-containing els as described. (B, below) c-los gene 
expression. Cardiac myocytes were pretreated for 30 min with rapamy- 
cin (0.5 ng/ml) or FK506 (10 ng/ml) and stimulated with 10 -6 M Ang 
II for 30 min. lane 1, control; lane 2, Ang II; lane 3, Ang II + rapamy- 
cin; lane 4, Ang II + FK506. Northern blot analysis was performed as 
described. Ethidium bromide staining of 18 S rRNA is presented to 
show that an equal amount of RNA (8 pg) was loaded in each lane. 
Similar results were obtained from two independent experiments. 
are necessary for p70 s6K activation are same as those for the 
activation of MAP kinases and p90 rsk [7-9]. 
The immunosuppressant gents rapamycin and FK506 are 
structurally related macrolides that have been reported to in- 
hibit proliferation and activation of T cells by binding the same 
cellular eceptor, FK506-binding protein (FKBP) [20,25-27]. It 
has been demonstrated that these two agents interfere with 
distinct signaling pathways after binding FKBP [21-23]. The 
FK506-FKBP complex binds Ca2+/calmodulin-dependent 
phosphatase, calcineurin, and inhibits its phosphatase activity 
[21]. In contrast, the rapamycin-FKBP complex inhibits the 
IL-2 signaling pathway which leads to activation of p70 s6K and 
cyclin-dependent kinases (CDKs), by binding to FKBP-ra- 
pamycin-associated protein (FRAP)/rapamycin and FKBP12 
targets (RAFT) [22,23]. A recent report has demonstrated that 
FRAP is a rapamycin-sensitive regulator of p70 s6r in vivo and 
that both the kinase activity and the amino-terminal domain of 
FRAP are required for control of p70 s6r [28]. Rapamycin 
blocked the Ang II-induced p70 s6K activation and also inhibited 
the increase in protein synthesis induced by Ang II at the same 
range of concentration i cardiac myocytes. These results ug- 
gest that activation of p70 s6K is necessary for the increase in 
protein synthesis induced by Ang II. 
Many reports have suggested that MAP kinases are activated 
by many growth factors and cytokines and play important roles 
in cell proliferation and differentiation [29]. Cowley et al. have 
reported that MAP kinase pathway mediates both differentia- 
tion of PC12 pheochromocytoma cells and transformation of
NIH 3T3 cells [30]. It has been reported that activated MAP 
kinases translocate into the nucleus and activate nuclear tran- 
scription factor Elk-1 resulting in the induction of c-fos gene 
expression [31]. p90 rsk has been reported to exist in downstream 
of MAP kinases and to phosphorylate nuclear lamins [32]. 
Rapamycin blocked the Ang II-induced p70 s6K activation but 
did not inhibit the activation of MAP kinases or the expression 
of c-fos gene induced by Ang II in cardiac myocytes. These 
results suggest hat Ang II activates p70 s6K through the path- 
way different from that of MAP kinases/p90 rsk. Recently it has 
been reported that MAP kinases phosphorylate PHAS-I, which 
is a heat-stable protein found in many tissues including the 
heart and the phosphorylated PHAS-I dissociates from transla- 
tion initiation factor 4E, resulting in the initiation of translation 
[33]. Therefore, it is possible that the activations of both p70 s6K 
and MAP kinases are necessary for Ang II-induced cardiac 
hypertrophy. ATI receptor is associated with the tetrameric 
GTP-binding protein, Gq. Further studies will be required to 
determine how Gq coupled Ang II receptor activates p70 s6K in 
cardiac myocytes. 
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